A phase I dose escalation and cohort expansion study of lirilumab (anti-KIR; BMS-986015) in combination with nivolumab (anti-PD-1; BMS-936558, ONO-4538) in advanced solid tumors.
Neil Howard Segal
Research Funding - Bristol-Myers Squibb
F. Stephen Hodi
No relevant relationships to disclose
Rachel E. Sanborn
Consultant or Advisory Role - Bristol-Myers Squibb
Thomas Gajewski
Consultant or Advisory Role - Bristol-Myers Squibb
Research Funding - Bristol-Myers Squibb
Jedd D. Wolchok
Consultant or Advisory Role - Bristol-Myers Squibb
Research Funding - Bristol-Myers Squibb
Walter John Urba
Consultant or Advisory Role - Bristol-Myers Squibb
Honoraria - Bristol-Myers Squibb
Research Funding - Bristol-Myers Squibb
Bernard A. Fox
Consultant or Advisory Role - Bristol-Myers Squibb
Research Funding - Bristol-Myers Squibb
Suzanne Louise Topalian
Consultant or Advisory Role - Bristol-Myers Squibb (U); Jounce Therapeutics; Sanofi
Research Funding - Bristol-Myers Squibb
Other Remuneration - Amplimmune; Bristol-Myers Squibb
Drew M. Pardoll
Consultant or Advisory Role - Aduro Biotech (U); Amplimmune (U); ImmuneXcite
Georgia Kollia
Employment or Leadership Position - Bristol-Myers Squibb
Stock Ownership - Bristol-Myers Squibb
Dan McDonald
Employment or Leadership Position - Bristol-Myers Squibb
Stock Ownership - Bristol-Myers Squibb
Su Young Kim
Employment or Leadership Position - Bristol-Myers Squibb
Stock Ownership - Bristol-Myers Squibb
William Howard Sharfman
No relevant relationships to disclose